These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 6897355)

  • 21. Podocyte architecture in puromycin aminonucleoside-treated rats administered tungsten or allopurinol.
    Ricardo SD; Bertram JF; Ryan GB
    Exp Nephrol; 1995; 3(5):270-9. PubMed ID: 7583048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical.
    Spector T
    Biochem Pharmacol; 1988 Jan; 37(2):349-52. PubMed ID: 2829916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of local hyperthermia on the pharmacokinetics of misonidazole in the anaesthetized mouse.
    Honess DJ; Workman P; Morgan JE; Bleehen NM
    Br J Cancer; 1980 Apr; 41(4):529-40. PubMed ID: 7387851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of allopurinol on caffeine disposition in man.
    Grant DM; Tang BK; Campbell ME; Kalow W
    Br J Clin Pharmacol; 1986 Apr; 21(4):454-8. PubMed ID: 3754760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of xanthine oxidase inhibition on ischemic acute renal failure in the rat.
    Zager RA; Gmur DJ
    Am J Physiol; 1989 Dec; 257(6 Pt 2):F953-8. PubMed ID: 2603962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Desmethylmisonidazole (Ro 05-9963): clinical pharmacokinetics after multiple oral administration.
    Stratford MR; Minchinton AI; Dische S; Saunders MI; Anderson P
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):377-9. PubMed ID: 7107355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative distribution of misonidazole and its amine metabolite in female Swiss Webster mice.
    Born JL; Hadley WM
    Int J Radiat Oncol Biol Phys; 1985 Jun; 11(6):1157-61. PubMed ID: 3997598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of hypoxic cell radiosensitizers: a review.
    Workman P
    Cancer Clin Trials; 1980; 3(3):237-51. PubMed ID: 7438321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between plasma oxipurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol.
    Day RO; Miners J; Birkett DJ; Graham GG; Whitehead A
    Br J Clin Pharmacol; 1988 Oct; 26(4):429-34. PubMed ID: 3190993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reductive activation of nitroaromatics and enzyme inhibition: misonidazole and xanthine oxidase.
    Raleigh JA; Liu SF; Shum FY
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):701-4. PubMed ID: 6896706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal capillary permeability and intravascular red cell aggregation after ischaemia. I. Effects of xanthine oxidase activity.
    Ojteg G; Bayati A; Källskog O; Wolgast M
    Acta Physiol Scand; 1987 Mar; 129(3):295-304. PubMed ID: 3577816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allopurinol: kinetics, inhibition of xanthine oxidase activity, and protective effect in ischemic-reperfused canine heart as studied by cardiac microdialysis.
    Kuzmin AI; Tskitishvili OV; Serebryakova LI; Kapelko VI; Majorova IV; Medvedev OS
    J Cardiovasc Pharmacol; 1995 Apr; 25(4):564-71. PubMed ID: 7596124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of nitroimidazoles on glucose utilization and lactate accumulation in mouse brain.
    Chao CF; Subjeck JR; Brody H; Shen J; Johnson RJ
    Radiat Res; 1984 Jan; 97(1):87-96. PubMed ID: 6695046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nephrotoxic effects of allopurinol in dinitrofluorobenzene-sensitized mice: comparative studies on TEI-6720.
    Horiuchi H; Ota M; Kaneko H; Kasahara Y; Ohta T; Komoriya K
    Res Commun Mol Pathol Pharmacol; 1999; 104(3):293-305. PubMed ID: 10741380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug metabolism and chemosensitization. Nitroimidazoles as inhibitors of drug metabolism.
    Workman P; Twentyman PR; Lee FY; Walton MI
    Biochem Pharmacol; 1983 Mar; 32(5):857-64. PubMed ID: 6838633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative pharmacokinetics, biodistribution, metabolism and hypoxia-dependent uptake of [18F]-EF3 and [18F]-MISO in rodent tumor models.
    Mahy P; De Bast M; de Groot T; Cheguillaume A; Gillart J; Haustermans K; Labar D; Grégoire V
    Radiother Oncol; 2008 Dec; 89(3):353-60. PubMed ID: 18649964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic considerations in testing hypoxic cell radiosensitizers in mouse tumours.
    Brown JM; Yu NY; Workman P
    Br J Cancer; 1979 Mar; 39(3):310-20. PubMed ID: 465300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal elimination of the hypoxic cell radiosensitizer misonidazole in Wistar rats: influence of some drugs on its excretion.
    Akel G; Canal P; Soula G
    Eur J Drug Metab Pharmacokinet; 1985; 10(3):181-7. PubMed ID: 4085520
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancement of melphalan-induced tumour cell killing by misonidazole: an interaction of competing mechanisms.
    Horsman MR; Evans JW; Brown JM
    Br J Cancer; 1984 Sep; 50(3):305-16. PubMed ID: 6466544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response of murine tumours to combinations of CCNU with misonidazole and other radiation sensitizers.
    Siemann DW
    Br J Cancer; 1982 Feb; 45(2):272-81. PubMed ID: 6460517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.